Literature DB >> 9658402

FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells.

A Philips1, C Teyssier, F Galtier, C Rivier-Covas, J M Rey, H Rochefort, D Chalbos.   

Abstract

We compared the effect of estradiol on activator protein-1 (AP-1) activity in estrogen receptor positive (ER alpha+) and estrogen receptor negative (ER alpha-) human breast cancer cell lines transiently transfected with the AP-1-responsive reporter plasmid AP-1-TK-CAT and an ER alpha expression vector. While estradiol increased AP-1 activity in the ER alpha+ cell lines MCF7, ZR75.1, and T47D, it decreased (MDA-MB231 and BT20 cells) or had no significant effect (MDA-MB435 cells) on AP-1-mediated transcription in ER alpha- cells. Estradiol also inhibited AP-1 activity in ER alpha-MDA-MB231 cells stably transfected with ER alpha and in which ER alpha levels are close to those found in MCF7. Use of ER alpha mutant expression vectors demonstrated that the DNA-binding domain of ER alpha was needed for stimulation or inhibition of AP-1 activity by estradiol but suggested that ER alpha binding to estrogen-responsive elements was not required for these effects. Changes in regulation paralleled quantitative and qualitative changes in protein binding to AP-1 sites, as demonstrated by gel shift assay: protein binding was greater and DNA/protein complexes migrated faster for ER alpha--than for ER alpha+ cells. In fact, by Northern blot, a high level of Fra-1 mRNA was found in BT20 and MDA-MB231 cells as compared with ER alpha+ cells, and MDA-MB435 cells showed an intermediary level of expression. The differential expression of Fra-1 in MCF7 and MDA-MB231 cells was confirmed at the protein level by supershift experiments. In addition, overexpression of Fra-1 in MCF7 cells decreased the positive effect of estradiol while inhibition of Fra-1 expression in MDA-MB231 cells, by transient transfection of the Fra-1 antisense expression vector, abolished the negative effect of the hormone. In conclusion, we demonstrated that ER alpha- breast cancer cell lines differ from ER+ cells by a high level of AP-1 DNA-binding activity due, at least in part, to high Fra-1 constitutive expression. High Fra-1 concentration is crucial for the negative regulation of AP-1 activity by estradiol and thus may take part in estradiol-induced inhibition of cell proliferation in ER alpha- breast cancer cells transfected with ER alpha expression construct.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658402     DOI: 10.1210/mend.12.7.0133

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  24 in total

1.  The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.

Authors:  K Belguise; S Milord; F Galtier; G Moquet-Torcy; M Piechaczyk; D Chalbos
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

2.  Prognostic impact of transcription factor Fra-1 in ER-positive breast cancer: contribution to a metastatic phenotype through modulation of tumor cell adhesive properties.

Authors:  L Oliveira-Ferrer; M Kürschner; V Labitzky; D Wicklein; V Müller; G Lüers; U Schumacher; K Milde-Langosch; C Schröder
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-10       Impact factor: 4.553

3.  Immunochemical analysis of protein expression in breast epithelial cells transformed by estrogens and high linear energy transfer (LET) radiation.

Authors:  Gloria M Calaf; Debasish Roy; Tom K Hei
Journal:  Histochem Cell Biol       Date:  2005-10-28       Impact factor: 4.304

4.  Oestrogens inhibit interleukin 1beta-mediated nitric oxide synthase expression in articular chondrocytes through nuclear factor-kappa B impairment.

Authors:  Pascal Richette; Marie-France Dumontier; Khadija Tahiri; Magdalena Widerak; Antoine Torre; Mourad Benallaoua; Mourad Benallaloua; François Rannou; Marie-Therese Corvol; Jean-François Savouret
Journal:  Ann Rheum Dis       Date:  2006-10-26       Impact factor: 19.103

5.  Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Authors:  Neil E Bhola; Valerie M Jansen; Sangeeta Bafna; Jennifer M Giltnane; Justin M Balko; Mónica V Estrada; Ingrid Meszoely; Ingrid Mayer; Vandana Abramson; Fei Ye; Melinda Sanders; Teresa C Dugger; Eliezer V Allen; Carlos L Arteaga
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

6.  Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism.

Authors:  Helene Pelicano; Weiqin Lu; Yan Zhou; Wan Zhang; Zhao Chen; Yumin Hu; Peng Huang
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

7.  Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization.

Authors:  Laura Casalino; Dario De Cesare; Pasquale Verde
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

8.  Mechanisms underlying differential expression of interleukin-8 in breast cancer cells.

Authors:  Ariane Freund; Valérie Jolivel; Sébastien Durand; Nathalie Kersual; Dany Chalbos; Carine Chavey; Françoise Vignon; Gwendal Lazennec
Journal:  Oncogene       Date:  2004-08-12       Impact factor: 9.867

9.  Synergistic activation of human involucrin gene expression by Fra-1 and p300--evidence for the presence of a multiprotein complex.

Authors:  James F Crish; Richard L Eckert
Journal:  J Invest Dermatol       Date:  2007-09-20       Impact factor: 8.551

10.  Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.

Authors:  Xiaobo Wang; Karine Belguise; Nathalie Kersual; Kathrin H Kirsch; Nora D Mineva; Florence Galtier; Dany Chalbos; Gail E Sonenshein
Journal:  Nat Cell Biol       Date:  2007-03-18       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.